What is known and objective: The pharmacokinetics (PK) and pharmacodynamics (PD) of levofloxacin were investigated following administration of levofloxacin injection in healthy Chinese volunteers for optimizing dosing regimen. Methods: The PK study included single-dose (750 mg/150 mL) and multiple-dose (750 mg/150 mL once daily for 7 days) phases. The concentration of levofloxacin in blood and urine was determined using HPLC method. Both non-compartmental and compartmental analyses were performed to estimate PK parameters. Taking fC max /MIC ≥5 and fAUC 24 h /MIC ≥30 as a target, the cumulative fraction of response (CFR) of levofloxacin 750 mg for treatment of community-acquired pneumonia (CAP) was calculated using Monte Carlo simulation. The probability of target attainment (PTA) of levofloxacin at various minimal inhibitory concentrations (MICs) was also evaluated. Results and discussion: The results of PK study showed that the C max and AUC 0-∞ of levofloxacin were 14Á94 lg/mL and 80Á14 lg h/mL following single-dose infusion of levofloxacin. The half-life and average cumulative urine excretion ratio within 72 h post-dosing were 7Á75 h and 86Á95%, respectively. The mean C ss,max , C ss,min and AUC 0-τ of levofloxacin at steady state following multiple doses were 13Á31 lg/mL, 0Á031 lg/mL and 103Á7 lg h/mL, respectively. The accumulation coefficient was 1Á22. PK/PD analysis revealed that the CFR value of levofloxacin 750-mg regimen against Streptococcus pneumoniae was 96Á2% and 95Á4%, respectively, in terms of fC max /MIC and fAUC/MIC targets. What is new and conclusion: The regimen of 750-mg levofloxacin once daily provides a satisfactory PK/PD profile against the main pathogenic bacteria of CAP, which implies promising clinical and bacteriological efficacy for patients with CAP. A large-scale clinical study is warranted to confirm these results.
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Levofloxacin is increasingly used in the treatment for communityacquired pneumonia (CAP) due to its potent bactericidal effect, higher blood drug concentration, extensive tissue distribution and higher bioavailability. [2] [3] [4] [5] The pharmacokinetic/pharmacodynamic (PK/PD) studies in recent years have proved that levofloxacin is a concentrationdependent antimicrobial agent. Its bactericidal activity increases with drug concentration over a certain range. It is proposed that the maximal bactericidal effect may be achieved by delivering fewer or single but high-level dose per day to maintain higher C max /MIC and AUC 0-24 /MIC ratios. Such a regimen may also be helpful to avoid the emergence of antibiotic resistance. For this reason, PK studies have been conducted for levofloxacin 750-mg injection (150 mL) in the United States and European countries. 6, 7 Intravenous administration of levofloxacin 750-mg injection (150 mL) once daily for 5 days achieved the same efficacy in severe CAP as the regimen of 500 mg once daily for 10 days. This new regimen has a shorter duration of treatment and lower exposure, less medical cost and may be associated with lower risk of developing resistance. 8, 9 However, no multiple-dose PK study of levofloxacin 750-mg IV infusion has been reported in Chinese subjects yet. It is necessary to clarify the PK/PD and safety profile of levofloxacin 750-mg IV infusion in Chinese volunteers for optimizing the dosing regimen.
This study was designed to explore the PK profiles of levofloxacin following single-dose and multiple-dose intravenous infusion of levofloxacin 750 mg for the first time in Chinese healthy volunteers. Meanwhile, considering the PD data of in vitro antimicrobial susceptibility testing for major CAP pathogens such as Streptococcus pneumoniae and Haemophilus influenzae, 10 Monte Carlo simulation (MCS) method was used to perform PK/PD analysis. The results were compared with the PK/PD profile of levofloxacin 500-mg injection. An optimized dosing regimen, which is expected to achieve the maximal bactericidal effect in vivo, is recommended for patients with severe CAP.
METHODS

Subjects
In the open-label single-dose study, nine enrolled healthy subjects received levofloxacin 750 mg/150 mL via intravenous infusion. In the randomized, double-blind, multiple-dose phase, 12 healthy subjects received levofloxacin 750 mg/150 mL or placebo (ratio of 3 : 1) via intravenous infusion over 90 min, once daily for seven consecutive days. The study protocol and informed consent were approved by the Institutional Ethics Committee. All subjects signed the written informed consent before participation in this study.
The nine male subjects in single-dose study were 23Á51 AE 2Á00 years of age and 65Á67 AE 4Á60 kg of body weight at average. Their creatinine clearance (CL cr ) was 138Á0 AE 13Á28 mL/min before study administration. The nine male subjects receiving levofloxacin in multiple-dose study were 24Á56 AE 2Á41 years of age and 60Á39 AE 4Á61 kg of body weight at average. Their CL cr was 125Á9 AE 16Á5 mL/min before study initiation. The three male subjects receiving placebo were 26Á24 AE 0Á98 years of age and 62Á00 AE 4Á27 kg of body weight. Their CL cr was 116Á6 AE 7Á6 mL/min.
Antimicrobial agent
Levofloxacin 750-mg injection (Cravit, Lot: EXH0701, 150 mL/bottle containing levofloxacin 0Á75 g and NaCl 1Á35 g) was the product of Daiichi Pharmaceutical (Beijing, China). Placebo was 0Á9% sodium chloride injection [Shanghai Huayuan Changfu Pharmaceutical (Group) Company, Lot: 07071104-1, 250 mL/bottle].
Single-dose study
Single dose of levofloxacin 750 mg was administered intravenously with an infusion pump at constant rate over 1Á5 h. Blood sample (5 mL) was drawn before infusion, 0Á75 h after infusion start and immediately, 0Á25, 0Á5, 1, 1Á5, 2, 3, 4, 8, 12, 24, 36, 48, 60 and 72 h after the end of infusion. All urine was collected according to the following intervals: before infusion, 0-2, 2-4, 4-8, 8-12, 12-24, 24-48 and 48-72 h after the end of infusion.
Multiple-dose study
Levofloxacin 750 mg was administered intravenously to the volunteers once daily with an infusion pump at constant rate over 1Á5 h for seven consecutive days. Blood sample (5 mL) was drawn before infusion, 0Á75 h after infusion start and immediately, 0Á25, 0Á5, 1, 1Á5, 2, 3, 4, 8 and 12 h after the end of infusion on Day 1, immediately before infusion (0 h) and immediately after the end of infusion from Day 2 to Day 6. The sampling time points on Day 7 were the same as that in single-dose study. All urine was collected on Day 1 and Day 7 according to the following intervals: before infusion, 0-2, 2-4, 4-8, 8-12 and 12-24 h. Urine volume was measured and recorded.
Sample processing and data collection
All the blood samples were put on ice bath and subjected to centrifugation within 30 min at 4°C (1500 9 g, 10 min) to separate plasma. The plasma was aliquoted to two tubes and stored at À40 AE 5°C in a refrigerator for later analysis.
The volunteers were observed for any adverse event since the start of infusion, including clinical observation, vital signs (temperature, blood pressure and pulse rate), laboratory tests (haematology, urinalysis and serum biochemical tests), 12-lead electrocardiogram for safety evaluation of levofloxacin.
Levofloxacin assay
High-performance liquid chromatography (HPLC) (Waters 2695 HPLC System, Waters Company, Milford, MA, USA) was used to determine levofloxacin concentration in blood and urine samples. The solid phase was TSK-gel ODS-80TM gel column (4Á6 mm 9 150 mm, 5 lm). The mobile phase contained 50 mmol/L KH 2 PO 4 (pH 2Á0), THF and 1 M CH 3 COONH 4 (92/ 7/1, V/V/V), respectively. The wavelength for fluorescence detection E x /E m was 296 nm/504 nm, column temperature was 35°C, flow rate was 1Á0 mL/min, and injection volume for plasma and urine samples was 10 lL and 20 lL, respectively. The retention time was about 6Á5 min for levofloxacin and 8Á5 min for the internal standard (DL-8493, lot number 900131, provided by Daiichi Pharmaceutical). The range of standard curve was from 0Á010 to 5Á000 lg/mL for plasma and 0Á100 to 100Á0 lg/mL for urine. The curve linearity was 0Á9989 and 0Á9998, respectively. The assay method and its validation were previously described by Zhang J et al.
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Pharmacokinetic calculation
Phoenix WinNonlin 6.0 software (Pharsight Company, Sunnyvale, CA, USA) was used to calculate the non-compartmental PK parameters of levofloxacin following administration of levofloxacin. Peak concentration (C max ) and C 24 h were expressed as the observed values. AUC 0-t was calculated based on the trapezoidal rule. Linear regression analysis was conducted using the terminal logarithmic concentration-time data to calculate the elimination rate constant (k). The terminal elimination half-life (T 1/2 ) was 0Á693/k. AUC 0-∞ was calculated as AUC 0-t + terminal concentration/k. The total clearance (CL t ) was calculated as the ratio of dose to AUC 0-∞ . Renal clearance (CL r ) was the ratio of levofloxacin cumulative urinary excretion to AUC 0-24 h . The apparent volume of distribution (V d ) is the ratio of CL t to k. The mean residence time (MRT 0-∞ ) was based on AUMC/AUC ratio. Two-compartment model was employed to analyse the PK profile of levofloxacin in healthy volunteers using WinNonlin software. The removal of levofloxacin from central compartment to peripheral compartment and the transport between central compartment and peripheral compartment were all consistent with first-order kinetics. The elimination rate and clearance were represented by K e and CL. The corresponding rate constant was expressed as K 12 and K 21 , respectively. The clearance between compartments was expressed as Q. The distribution volume of central and peripheral compartments was represented by V 1 and V 2 . The rate of distribution phase and elimination phase was represented by a and b, whereas the corresponding half-life was expressed as T 1/2 , a and T 1/2, b . The weight of 1/C was used in the calculation.
Statistical analysis
The non-compartmental parameters of levofloxacin following multiple doses were compared between Day 1 and Day 7 to evaluate the PK behaviours over time following multiple doses, for example, the change in T 1/2 and drug accumulation. The compartmental parameters of levofloxacin following single-or multiple-dose administration were compared to analyse the details of levofloxacin PK profile.
The correlation between compartmental parameters of levofloxacin and the relevant demographic covariates was also evaluated to preliminarily examine the potential factors influencing the disposition of levofloxacin in healthy adults. The data sets were examined by F-test for homogeneity of variance. The homogeneous data were compared by t-test between groups. Statistical significance was assumed at the level of P < 0Á05. The above statistical analyses were completed with SPSS software package (Version 13.0, IBM SPSS Software, Armonk, NY, USA). The results were expressed as Mean AE SD.
Safety evaluation
The Criteria for Evaluation of Adverse Drug Reactions and Laboratory Abnormalities due to Antimicrobial Agents in Clinical Study issued by Japanese Society of Chemotherapy were referred to in this study to confirm the adverse events and the severity (mild, moderate and severe). The relationship between an adverse event and the study drug was judged as definitely, probably, possibly related, or possibly unrelated, unrelated or indeterminate. The events definitely, probably, possibly related to the study drug or indeterminate were classified as adverse drug reactions. In this study, the adverse events leading to study discontinuation, or requiring treatment, or resulting in QTc prolongation (≥60 msec longer or QTc interval ≥500 msec) were taken as significant adverse events.
PK/PD analysis and dosing regimen evaluation PK/PD analysis was performed and evaluated for levofloxacin 750-mg dosing regimen based on the PK parameters of levofloxacin at steady state following dosing of 750 mg daily for seven consecutive days in this study, and the pharmacodynamic data from two clinical trials were as follows: levofloxacin tablet 500 mg in 881 patients with CAP or other lower respiratory tract infections during 2006-2007, and randomized controlled study of levofloxacin injection 750 mg vs. 500 mg in CAP during 2007-2008. 10 Monte Carlo simulation was used to conduct the PK/PD analysis. The simulation was performed in 5000 patients with MATLAB software version 7.0.1 (Mathworks Company, Natick, MA, USA). It is expected to obtain a target PK/PD value indicating satisfactory clinical and bacteriological efficacy if fC max /MIC ≥5 and/or fAUC 24 h /MIC ≥30. 12 The protein-binding rate of levofloxacin is 30%; hence, the fraction of free drug (f) is 0Á7. The cumulative fraction of response (CFR) was calculated for 750-mg levofloxacin regimen in attaining the above target PK/PD value specific for major CAP pathogens. The susceptibility break point of levofloxacin against Streptococcus pneumoniae is ≤2 lg/mL. 13 Therefore, this calculation is the pharmacodynamic probability of target attainment (PTA) in terms of fC max /MIC ≥5 and fAUC 24 h /MIC ≥30 when MIC = 0Á25, 0Á5, 1 or 2 lg/mL. In Monte Carlo simulation, the simulated steady-state AUC 0-24 h and C max data were generated based on logarithmic normal distribution. The simulated MIC data were generated based on discrete distribution according to specified probability at each MIC level.
RESULTS
Levofloxacin pharmacokinetics
The PK parameters in the nine subjects following single intravenous dose of levofloxacin 750 mg showed mean C max (14Á94 AE 1Á48) lg/mL, AUC 0-72 h (79Á97 AE 12Á53) lg h/mL and AUC 0-∞ (80Á14 AE 12Á55) lg h/mL. The terminal elimination halflife (t 1/2 ) was (7Á75 AE 0Á59) h. Renal clearance (CL r ) and CL t were (8Á17 AE 1Á00) L/h and (9Á58 AE 1Á62) L/h, respectively. The distribution volume (V d ) was (107Á30 AE 20Á73) L. The cumulative urinary excretion of levofloxacin was (86Á95 AE 5Á04)% of the administered dose 72 h post-dose (Table 1) .
In the nine subjects receiving multiple-dose intravenous infusion of levofloxacin 750 mg once daily for seven consecutive days, the C max was (17Á69 AE 4Á23) lg/mL on Day 1 and (13Á31 AE 2Á77) lg/mL on Day 7. The plasma concentration of levofloxacin at 24 h was (0Á87 AE 0Á22) lg/mL on Day 1 and (0Á803 AE 0Á258) lg/mL on Day 7. The corresponding AUC 0-24 h was (90Á05 AE 11Á92) lgÁh/mL and (94Á1 AE 15Á2) lg h/mL. The Table 1 . Non-compartmental and compartmental parameters of levofloxacin following intravenous infusion of levofloxacin 750 mg in healthy Chinese volunteers (n = 9, Mean AE SD)
43Á4 AE 9Á97 e a P < 0Á05. b P < 0Á01 vs. single-dose PK (non-compartmental parameter). c P < 0Á05. d P < 0Á01 vs. multiple-dose PK (first dose, non-compartmental parameter).
e mean 24-hour cumulative urinary excretion rate was (75Á69 AE 6Á34)% and (84Á16 AE 5Á14)% of the administered dose, respectively. When steady state was reached following consecutive dosing, the mean C ss,max of levofloxacin was 13Á31 lg/mL, mean C ss,min 0Á031 lg/mL, average plasma concentration (C avg ) (3Á87 AE 0Á62) lg/mL, mean AUC 0-τ 94Á12 lg h/mL (τ = 24 h) and accumulation factor (1Á22 AE 0Á14) ( Table 1 ). Further analysis indicated that the ratio of geometric mean C max , C 24 h , AUC 0-24 h (Day 7/Day 1) and the corresponding 95% confidence interval were 0Á76 (0Á61-0Á95), 0Á91 (0Á78-1Á06) and 1Á04 (0Á97-1Á11), suggesting no apparent accumulation in the body when steady state was reached following once-daily administration of levofloxacin for 7 days.
Compartmental model analysis
Two-compartment model well described the PK profile of levofloxacin in healthy volunteers following single-or multiple-dose administration (Fig. 1) . The results showed that the distribution half-life after single dose of levofloxacin was (1Á02 AE 0Á32) h. The distribution volume of central and peripheral compartments was (67Á8 AE 13Á2) L and (29Á2 AE 7Á61) L, respectively. The clearance from central compartment was (10Á2 AE 1Á89) L/h and (13Á8 AE 5Á6) L/h between central and peripheral compartments.
Safety of levofloxacin
Six ADRs were reported in 6 of the 9 subjects receiving single dose of levofloxacin. The ADR was local adverse reaction in four subjects, that is, mild injection site hyperaemia, which started within 16-45 min since intravenous infusion, and resolved 30 min after the end of intravenous infusion. Both the increased lactate dehydrogenase in one subject and the conjugated bilirubin elevation in another subject developed 23 h after the end of intravenous infusion and normalized at Day 7 post-dose visit. All these ADRs were mild, transient and well tolerated.
Nine adverse events occurred in 8 of the 9 subjects receiving multiple doses of levofloxacin. Eight of these events in seven subjects were ADRs. Six ADRs were intermittent mild injection site hyperaemia during the consecutive 7-day intravenous infusion and resolved within 10-25 min after the end of intravenous infusion the same day. Two cases of laboratory abnormalities were transient creatine kinase elevation and increased total bilirubin. The increase was within two times the upper limit of normal in both cases. These ADRs were mild in severity and well tolerated. One of the three subjects receiving placebo developed two mild adverse events (decreased white blood cell count and increased uric acid), which were unrelated to the study drug.
Other laboratory tests, vital signs and 12-lead ECG parameters were all within the normal range in both single-dose and multipledose studies. No fatal or other significant adverse events were found. There was no significant adverse event leading to study discontinuation or abnormal QTc interval. was 95Á4%, 98Á0%, 95Á2% and 100Á0% in terms of fAUC 24 h / MIC = 30, whereas for MRSA, the CFR was 0. From Fig. 3 , when MIC ≤1 lg/mL, the PTA of levofloxacin 750-mg dosing regimen was kept at 100% in terms of the target value of fC max /MIC or fAUC 24 h /MIC, suggesting that levofloxacin 750-mg dosing regimen can promise good clinical and microbiological efficacy targeting the bacteria for which levofloxacin MIC ≤1 lg/ mL.
PK/PD analysis and dosing regimen evaluation
DISCUSSION
Following single-or multiple-dose intravenous infusion of levofloxacin 750 mg in healthy Chinese male volunteers, the C max of levofloxacin was 14Á94 lg/mL and 13Á31 lg/mL; AUC 0-24 73Á26 lg h/mL and 94Á12 lg h/mL; T 1/2 7Á75 h and 6Á91 h. These findings were comparable with the results reported by Chow et al., 6 which indicated that after single-or consecutive 10-day multiple-dose intravenous infusion of levofloxacin 750 mg, the C max was 11Á3 mg/L and 12Á4 mg/L, AUC 0-24 90Á9 mg h/L and 103 mg h/L, and T 1/2 7Á51 h.
The multiple-dose PK profile of levofloxacin showed more rapid terminal elimination and lower apparent volume of distribution compared with that after single-dose intravenous infusion (Table 1) . This is reflected in the parameters of compartmental model, that is, both the clearance from central compartment and distribution volume decreased significantly (P < 0Á01). Furthermore, the distribution rate of levofloxacin was significantly increased; meanwhile, the clearance between compartments and the distribution volume of peripheral compartment were also significantly higher following multiple-dose infusion. These results indicate that after levofloxacin multiple-dose infusion, the centralto-peripheral compartment distribution is faster. A fraction of levofloxacin was transported from central-to-peripheral compartment, reflecting the high tissue penetration and extensive, highlevel distribution to peripheral tissues. This is helpful for levofloxacin to reach effective bactericidal concentration at the site of infection.
The distribution volume of levofloxacin is quite large, 1Á64 L/kg on average, following single dose of 750 mg. This indicates that levofloxacin is distributed widely in tissues and body fluids. It is reported that levofloxacin can be extensively distributed to the skeletal muscle intercellular fluid, inflammatory blister fluid, subcutaneous soft tissue and pulmonary tissue; especially in lungs and bronchi, the concentration of levofloxacin is two times higher than that in blood. The subjects in this study were all healthy volunteers without infectious respiratory disease. Several studies reported that the levofloxacin concentration in the pulmonary tissue and alveolar fluid was higher than the corresponding concentration in blood in the patients with respiratory tract infection, and the levofloxacin concentration in the blood of the patients with infection was higher than that in healthy volunteers. Therefore, levofloxacin can reach higher concentration in the tissues and body fluids of the patients with infection compared with healthy volunteers. [14] [15] [16] [17] [18] [19] [20] [21] Correlation analysis showed that the endogenous creatinine clearance (CL cr ) was well correlated with levofloxacin clearance (CL) in healthy subjects. Pearson's correlation coefficient (R) was 0Á529 (P < 0Á05). The body weight of volunteers was also correlated significantly with CL (R = 0Á573, P < 0Á01). The body weight of volunteers was positively correlated with the distribution volume of central compartment (R = 0Á443). The distribution volume of peripheral compartment showed a trend of increase with age (R = 0Á525, P < 0Á01). This implies that age of volunteers may be an important factor influencing the distribution volume of levofloxacin in peripheral compartment. The endogenous creatinine clearance and body weight are covariates affecting the external clearance. This finding is consistent with the results of levofloxacin population PK study.
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In our previous study of levofloxacin 500 mg, 22 after intravenous infusion of levofloxacin 500 mg, the mean C max and AUC 0-∞ were (7Á6 AE 1Á1) lg/mL and (38Á3 AE 4Á9) lg h/mL, respectively. The average terminal elimination half-life (T 1/2 ) was (6Á5 AE 0Á6) h. The CL r and CL t were (8Á8 AE 1Á4) L/h and (13Á3 AE 1Á7) L/h, respectively. V d was (109Á8 AE 10Á8) L. At 24 h after dosing, the cumulative urinary excretion was (65 AE 4)% of the administered dose. According to the PK parameters of levofloxacin 750-mg and 500-mg studies, as well as the PD data (results of susceptibility testing of 245 strains of bacteria) from two clinical trials previously conducted in our institute, 10 fC max /MIC 90 and fAUC 24 h /MIC 90 were calculated. The results demonstrated that except MRSA, both levofloxacin 750-mg and 500-mg dosing regimens can attain or exceed the target of fC max /MIC ≥5 and fAUC 24 h /MIC ≥30 for the common bacterial pathogens of CAP. Levofloxacin 750 mg provided higher PTA values than 500 mg (Table 2) .
Monte Carlo simulation indicated that the CFR of levofloxacin 750-mg and 500-mg dosing regimens was 96Á2% and 79Á5% for Streptococcus pneumoniae, a common pathogen of CAP, in terms of fC max /MIC ≥5. Similarly, the CFR of these two regimens was 95Á4% and 52Á9% in terms of fAUC 24 h /MIC ≥30. When MIC ≤0Á5 lg/mL, both dosing regimens offered best PTA (100%) in terms of fC max /MIC ≥5 and fAUC 24 h /MIC ≥30 for the common pathogens of CAP. When MIC = 1 lg/mL, the PTA for levofloxacin 750-mg dosing regimen was 99Á9% vs. 73Á7% for 500-mg dosing regimen in terms of fC max /MIC ≥5, and 99Á9% vs. 18Á6% in terms of fAUC 24 h /MIC ≥30. This suggests 750-mg dosing regimen of levofloxacin has higher probability in reaching the PD targets.
WHAT IS NEW AND CONCLUSION
Considering the concentration-dependent PK/PD property of levofloxacin, which means higher blood concentration predicts better bactericidal activity, it is expected that the regimen of levofloxacin 750-mg q.d. will provide more potent bactericidal activity in human body and maintain effective bactericidal concentration at infection site. Such a dosing regimen can shorten treatment duration and decrease the exposure to sub-MIC level of levofloxacin, which can potentially reduce the emergence of resistant bacteria.
The results of this study provide positive evidence to support the regimen of levofloxacin 750-mg injection (150 mL) once daily via intravenous infusion for 5 days in the treatment for severe CAP. It is necessary to design a large-scale clinical trial in patients to confirm these results. The f means the unbound fraction of levofloxacin, the value of which was 0Á7. The C max and AUC 0-24 were the non-compartmental paramters following last dose of levofloxacin in the multiple PK study.
